Japan’s ruling coalition sustained a crushing blow in the Lower House election last month, only managing to win 215 seats,…
HOME > ORGANIZATION
ORGANIZATION
- Wholesale Industry FTC to “Watch Closely” How Drug Makers Respond to Tougher Rules on Business Entertaining
March 7, 2012
- KSLION to Stimulate Innovation in Life Science in Japan: Prof. Y. Natsumeda
March 5, 2012
- Generic Drug Share Reaches 23.6% in 3rd Quarter of FY2011: JGA
March 2, 2012
- EFPIA Japan Chairman Fauchet Says New Committee to Review Health Economic Assessment
March 1, 2012
- Daiichi-Sankyo, Eisai, Pfizer Japan Leaving Strongest Impression at Dispensing Pharmacies: NPhA Survey
February 29, 2012
- JPWA President Bessho Welcomes NPhA’s Efforts for Drug Distribution Improvement
February 29, 2012
- JPA Incumbent President Kodama Reelected as Next Term Candidate
February 28, 2012
- Sales by Member Companies Rose 5% in 2011: JCROA
February 28, 2012
- NPhA Refers Plan to Recommend Next President to Board Review
February 27, 2012
- Toshiki Iwasaki to Step Down as NPhA President in May
February 24, 2012
- JSCTR to Set Up“GCP Expert” Certification to Improve Quality of Clinical Studies
February 21, 2012
- Japan Pharmaceutical Political Association Chairman Kumakura to Focus on Resolving Price Difference
February 21, 2012
- Prof. Kimura of Saga Univ. Receives Top Award for Research on Ubiquilin 1 Inhibitor
February 17, 2012
- 12 Organizations from 11 Countries, Regions to Participate in Asian Cooperation Conference
February 16, 2012
- JPMA VP Nogimori Focused on Thorough Compliance, Promotion of International Cooperation
February 15, 2012
- KIF5B-RET Fusion Gene Identified as Potential Target in Pulmonary Adenocarcinoma
February 13, 2012
- NPhA Compiles Draft Proposal for Mutual Understanding to Improve Distribution
February 10, 2012
- MHLW “Missing the Bigger Picture” in Measures to Eliminate Drug Lag: Prof. Nakamura
February 10, 2012
- PhRMA Concerned that Health Economic Evaluation Will Be Used to Reduce NHI Prices: Mr Zulueta
February 6, 2012
- JACDS to Strengthen Support to Ensure Compliance in Sale of OTC Drugs
February 6, 2012
ページ
For over two decades, Morunda has been at the forefront of interviewing and understanding leaders within Japan’s dynamic healthcare industry, particularly in pharmaceuticals and medical devices. What sets apart successful country managers in this competitive arena isn’t just their professional…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…